The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and Transformation  by Song, Su Jung et al.
Cell Stem Cell
ArticleThe Oncogenic MicroRNA miR-22 Targets the TET2
Tumor Suppressor to Promote Hematopoietic
Stem Cell Self-Renewal and Transformation
Su Jung Song,1,2,3,4,9 Keisuke Ito,1,2,3,4,9,10 Ugo Ala,1,2,3,4 Lev Kats,1,2,3,4 Kaitlyn Webster,1,2,3,4 Su Ming Sun,6
Mojca Jongen-Lavrencic,6 Katia Manova-Todorova,7 Julie Teruya-Feldstein,8 David E. Avigan,5 Ruud Delwel,6
and Pier Paolo Pandolfi1,2,3,4,*
1Cancer Genetics Program, Beth Israel Deaconess Cancer Center
2Department of Medicine, Division of Genetics, Beth Israel Deaconess Medical Center
3Department of Pathology, Beth Israel Deaconess Medical Center
4Division of Genetics, Beth Israel Deaconess Medical Center
5Division of Hematology and Oncology, Beth Israel Deaconess Medical Center
Harvard Medical School, Boston, MA 02215, USA
6The Institute for Hematology, Erasmus Medical Center, Rotterdam 5201, Netherlands
7Molecular Cytology
8Department of Pathology
Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
9These authors contributed equally to this work
10Present address: Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Departments of Cell
Biology/Stem Cell Institute and Medicine, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA
*Correspondence: ppandolf@bidmc.harvard.edu
http://dx.doi.org/10.1016/j.stem.2013.06.003SUMMARY
MicroRNAs are frequently deregulated in cancer.
Here we show that miR-22 is upregulated in myelo-
dysplastic syndrome (MDS) and leukemia and its
aberrant expression correlates with poor survival.
To explore its role in hematopoietic stem cell function
and malignancy, we generated transgenic mice con-
ditionally expressing miR-22 in the hematopoietic
compartment. These mice displayed reduced levels
of global 5-hydroxymethylcytosine (5-hmC) and in-
creasedhematopoietic stemcell self-renewal accom-
panied by defective differentiation. Conversely, miR-
22 inhibition blocked proliferation in both mouse
and human leukemic cells. Over time, miR-22 trans-
genicmice developedMDS and hematological malig-
nancies. We also identify TET2 as a key target of
miR-22 in this context. Ectopic expression of TET2
suppressed the miR-22-induced phenotypes. Down-
regulation of TET2 protein also correlated with poor
clinical outcomes and miR-22 overexpression in
MDS patients. Our results therefore identify miR-22
as a potent proto-oncogene and suggest that aber-
rations in the miR-22/TET2 regulatory network are
common in hematopoietic malignancies.
INTRODUCTION
Epigenetic mechanisms such as DNA methylation and histone
modification drive stable and clonally propagated changes ingene expression and have recently been shown to serve as
molecular mediators of pathway dysfunction in neoplasia
(Esteller, 2008; Rodrı´guez-Paredes and Esteller, 2011). Indeed,
both myelodysplastic syndrome (MDS) and leukemias are char-
acterized by frequent epigenetic abnormalities and aberrant
DNA hypermethylation has been linked to poor prognosis in
cases of MDS, as it is associated with more rapid progression
to acute myeloid leukemia (AML) (Shen et al., 2010; Shih et al.,
2012). Importantly, genome-wide discovery efforts in patients
with myeloid malignancies have led to the identification of a
number of causal genetic abnormalities that impact the
epigenetic landscape. These genes include TET2, IDH1, IDH2,
DNMT3a, and EZH2, all of which affect DNA and/or histone
lysine methylation (Shih et al., 2012).
Recent studies have examined in detail one such gene, TET2
(ten-eleven-translocation gene 2), which is located in 4q24 and
whose mutation or deletion is extremely frequent in hematolog-
ical malignancies, affecting 19% of patients with MDS, 12% of
patients with myeloproliferative neoplasm (MPN), and 24%
of patients with secondary AML (Abdel-Wahab et al., 2009;
Delhommeau et al., 2009; Jankowska et al., 2009; Tefferi et al.,
2009). TET2 mutations are observed in CD34+ progenitor cells
and are detected most frequently after MPN and MDS progres-
sion to AML (Abdel-Wahab et al., 2010).
TET2 catalyzes the oxidation of 5-methylcytosine (5-mC) to
5-hydroxymethylcytosine (5-hmC) and is known to control
hematopoiesis, presumably by regulating gene expression
through its effect on DNA methylation (Branco et al., 2012; Ito
et al., 2011; Ko et al., 2010; Shih et al., 2012). Tet2 deficiency
in mice impairs 5-mC hydroxylation and leads to skewed
differentiation, as well as enhancement of the self-renewal and
repopulating capacity of hematopoietic stem cells (HSCs). This
in turn promotes malignant transformation in mice, causingCell Stem Cell 13, 87–101, July 3, 2013 ª2013 Elsevier Inc. 87
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Regulation of TET2 by miR-22 in Hematopoiesisdisorders resembling MDS and MPN, as well as chronic myelo-
monocytic leukemia (CMMoL) (Moran-Crusio et al., 2011;
Quivoron et al., 2011). Recent studies have likewise shown that
leukemia-associated Isocitrate Dehydrogenase (IDH) 1 or 2
mutant enzymes can induce carboxylation of glutamine-derived
a-ketoglutarate (a-KG), with a concomitant increase in synthesis
of 2-hydroxyglutarate (2-HG), an inhibitory metabolite of TET2
(Figueroa et al., 2010; Sasaki et al., 2012). Collectively, these
studies implicate functional and mutational losses of TET2
as key events underlying aberrant hematopoiesis and leukemo-
genesis, in turn suggesting that the inactivation of TET2 function
by additional upstream cues could play a critical role in hemato-
logical malignancies.
MicroRNA (miRNA) deregulation is also known to contribute to
hematological malignancies, including MDS and AML (Bartel,
2004; Chen et al., 2004; Gangaraju and Lin, 2009). A combined
approach involving assessment of miRNA expression (using
microarrays) and bioinformatic prediction of mRNA targets has
revealed that distinct miRNA signatures fine-tune each step of
hematopoiesis, including the reconstitution potential of HSCs
(Arnold et al., 2011; Gangaraju and Lin, 2009). In turn, miRNAs
that target critical leukemia suppressors could act as powerful
proto-oncogenes in the hematopoietic compartment (Calin and
Croce, 2006).
In this study, we demonstrate that miR-22 controls hemato-
poiesis and HSC maintenance by negatively regulating TET2
protein levels. Importantly, we identify miR-22 as an epigenetic
modifier and the key oncogenic determinant for the pathogen-
esis of MDS and hematological malignancies in vivo, findings
with prognostic and critical therapeutic implications for a large
number of hematological disorders.
RESULTS
miR-22 Is Highly Expressed in Human Hematological
Malignancies and Increases the Replating Ability
of HSCs
In order to build on the insights of miRNA biology into epigenetic
alterations in myeloid malignancies, we attempted to identify
those miRNAs playing a critical role in the pathogenesis of the
stem cell disorder MDS and its progression to overt leukemia.
We first analyzed a previously reported miRNA microarray
profiling database and found that miR-22 is markedly upregu-
lated in patients with MDS (Figures S1A and S1B available on-
line; Dostalova Merkerova et al., 2011). These results prompted
us to perform expression analysis by in situ hybridization in a
large set of patient samples, which included bone marrow with
no sign of disease (n = 37), early stage MDS (refractory anemia
[RA], 5q syndrome [5q-], refractory cytopenia with multilineage
dysplasia [RCMD], and RA with ringed sideroblasts [RARS])
(n = 40), and RA with excess blasts (RAEB) (n = 67). Our com-
prehensive in situ hybridization analysis revealed that miR-22
is highly expressed in patients with MDS (Figure 1A and Fig-
ure S1C). We next estimated the survival rates of the sets of
MDS patients by using a Kaplan-Meier analysis and applied a
log-rank test to compare the survival rates of MDS patients on
the basis of miR-22 expression levels. Remarkably, we found
that aberrant expression of miR-22 directly correlates with
poor survival rates in patients (Figure 1B). It is noteworthy that88 Cell Stem Cell 13, 87–101, July 3, 2013 ª2013 Elsevier Inc.the distribution of blasts into each World Health Organization
(WHO) category of MDS stages was not directly associated
with the expression level of miR-22, but a significant correlation
between miR-22 levels and poor survival rates was observed
within each WHO classification, as well as among MDS patients
harboring a normal karyotype (Figures S1D–S1F). This indicates
that the poorer survival expectancy linked to miR-22 overex-
pression does not simply reflect confounding factors such as
blast count and cytogenetic karyotype. Taken together, these
findings led us to investigate the role of miR-22 in the hemato-
poietic system and the genesis of hematological malignancies.
To explore the function of miR-22 in hematopoiesis and leuke-
mia, we first transduced mouse hematopoietic stem/progenitor
cells (HSPCs; c-KitposSca-1posLinneg, hereafter referred to as
KSL cells) isolated from wild-type donor mice with either a retro-
viral vector encoding miR-22 and a green fluorescent protein
(GFP) or a control vector encoding GFP only. The GFP-express-
ing KSL cells were then resorted by flow cytometry and plated in
methylcellulose for an in vitro colony-forming unit (CFU) assay
(Figure S1G). We observed in the first plating that the cells
expressing miR-22 produced fewer colonies compared to
control cells; however, when GFP+KSL cells were resorted and
replated, miR-22-transduced cells produced more colonies in
the second plating (Figure S1H). Strikingly, these cells alsomain-
tained this ability throughout serial replatings: whereas control
cells only formed colonies in the first two platings, miR-22-
expressing KSL cells were able to produce colonies after
being replated at least seven times (Figure S1H). Microscopic
analysis of the cells from these colonies revealed a homogenous
blast-like morphology (Figure S1I, top). Consistent with these
results, miR-22-expressing KSL cellsmaintained their character-
istics and c-Kit expression (a marker of undifferentiated cells)
during their replatings (Figure S1I, bottom and Figures S1J
and S1K). To ensure that miR-22-transduced and control cells
were subjected to the same experimental treatment, we also
performed an in vitro competitive colony assay by mixing GFP+
KSL cells expressing miR-22 and GFP control KSL cells (Fig-
ure S1L, top). This analysis confirmed that miR-22-expressing
GFP+, but not GFP, KSL cells remained mostly in colonies
through consecutive replatings (Figure S1L, bottom). Taken
together, these data suggest that miR-22 can drive aberrant
replating capacity of HSPCs and may contribute to malignant
transformation.
miR-22 Affects HSC Biology In Vivo
We next sought to examine the biological effects of miR-22
in vivo and generated a conditional transgenic mouse model
overexpressing miR-22 in the hematopoietic compartment (Fig-
ure S2A). miR-22 expression was induced byMx1-Cre-mediated
excision of a LoxP flanked transcriptional STOP cassette by
administration of seven doses of polyinosine-polycytidine
(pIpC) over 14 days (Figures S2B and S2C). Two weeks
after pIpC administration, we isolated KSL cells from miR-
22F/+;Mx1-Cre mice and Mx1-Cre littermate controls and
analyzed their properties by using CFU and long-term culture-
initiating cell (LTC-IC) assays (Figures 1C–1G and Figure S2D).
In agreement with our previous retroviral transduction experi-
ments, we found that KSL cells from miR-22F/+;Mx1-Cre
transgenic mice displayed an enhanced replating potential
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Figure 1. miR-22 Is Upregulated in MDS Pa-
tients and Leads to Increased Replating Ca-
pacity In Vitro
(A) miR-22 is highly expressed in MDS patient
samples. Expression levels of miR-22 in blasts in
subtypes of MDS were measured by in situ hy-
bridization analysis. Normal (n = 37), RA (n = 30),
5q- (n = 5), RCMD (n = 4), RARS (n = 1), RAEB-1
(n = 32), and RAEB-2 (n = 35) are shown. Repre-
sentative images of in situ hybridization for miR-22
in MDS patients and normal bone marrow are
also shown (left). Insets of panels show miR-22
staining in blasts (arrow with B) and in differenti-
ated myeloid cells (e.g., neutrophil, arrow with M)
with a high magnification. The expression levels
of miR-22 were also scored as described in the
Supplemental Experimental Procedures (right).
The data were analyzed by Chi-square test. r,
Pearson’s r. Scale bars, 60 mm.
(B) miR-22 overexpression correlates with poor
survival rates of human MDS patients. MDS
patients were divided into two groups; low-miR-
22-expressing patients’ group (miR-22 Score 1 or
2, n = 49, blue) and high-miR-22-expressing
patients’ group (miR-22 Score 3, n = 58, red).
Overall survival of these patients is demonstrated.
p value was generated by a log-rank test.
(C) Overview of the experimental design for
the conditional miR-22 expression in the hema-
topoietic compartment. Two-month-old miR-
22F/+;Mx1-Cre mice or Mx1-Cre littermate con-
trols were treated with pIpC for two weeks. Two
weeks after pIpC administration, c-Kitpos
Sca-1posLinneg (KSL) cells were sorted to evaluate
the characteristics of miR-22-expressing he-
matopoietic stem/progenitor cells. LTC-IC, long-
term culture -initiating cells; BMT, bone marrow
transplantation.
(D) Colony-forming capacity of miR-22-expressing
progenitor cells. Two weeks after pIpC adminis-
tration, sorted KSL cells from miR-22F/+;Mx1-Cre
mice or littermate controls were cultured in
semisolid medium. Counting and classification
of colonies were performed in independent
littermate pairs (n = 3). GEMM, Colony-forming
unit-granulocyte, erythroid, macrophage, and
megakaryocyte; GM, Colony-forming unit-granulocyte and macrophage; M, Colony-forming unit-macrophage; E, Burst-forming unit-erythroid.
(E) miR-22 expression retains the ability to serially replate and generate colonies. In vitro colony replating assaywas performed as shown in Figure S2D and colony
counts in the indicated replatings were scored (n = 3). N.D., nondetectable.
(F) Ectopic expression of miR-22 results in an increase of HSPCs in in vitro long-term culture with stromal cells. KSL cells isolated as described in (C) were
cocultured with OP-9 stromal cells for 2 weeks. Maintained Linneg cells and KSL cells were evaluated (n = 3). Representative flow cytometry data of Linneg and the
KSL cells (left) are shown.Mean percentage ± SDof KSL cells in Linneg cells (middle) andmean absolute numbers ± SDof CD45posKSL cells (right) are also shown.
(G) miR-22 increases the myeloid compartment. The percentages of CD45pos cells (left), CD11bpos cells (middle), or Gr-1pos cells (right) in total mononuclear cells
(MNCs) were investigated 2 weeks after the coculture with stromal cells from (F) (n = 3).
All error bars represent ± SD. See also Figures S1, S2A–S2D, and S7.
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Regulation of TET2 by miR-22 in Hematopoiesis(Figures 1D and 1E). Furthermore, ectopic expression of miR-22
caused a robust increase in the number of both KSL and mature
myeloid cells, as determined by LTC-IC assay, indicating that
miR-22 enhances HSPC maintenance and predisposes those
cells to differentiate into the myeloid lineage (Figures 1F and 1G).
Next, we examined the ability of miR-22-overexpressing
HSPCs to compete with wild-type counterparts in vivo by utiliz-
ing an in vivo competitive transplantation assay. KSL cells from
miR-22F/+;Mx1-Cre and Mx1-Cre mice (Ly45.2) were purified
2 weeks after pIpC administration, mixed with Ly45.1/Ly45.2competitor bone marrow mononuclear cells (BM MNCs), and
transplanted into lethally irradiated Ly45.1 congenic recipient
mice. The ability of donor cells to contribute to the reconstitution
was then determined by flow cytometric analysis of peripheral
blood stained for Ly45.1 and Ly45.2. Within 3 weeks of trans-
plantation, donor cells from miR-22F/+;Mx1-Cre mice exhibited
a slight increase in chimerism compared to those from control
animals (Figure S2E). Over time this difference became more
pronounced asmiR-22F/+;Mx1-Cre KSL cells outcompeted their
wild-type counterparts (Figures 2A–2C and Figure S2F). AtCell Stem Cell 13, 87–101, July 3, 2013 ª2013 Elsevier Inc. 89
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Figure 2. miR-22 Leads to an Enhanced Re-
populating Capacity of HSPCs In Vivo
(A and B) Ly45.1 recipient mice were transplanted
with 1,500 KSL cells frommiR-22F/+;Mx1-Cremice
(n = 15) or littermate controls (n = 10) after pIpC
administration together with 4 3 105 Ly45.1/
Ly45.2 competitor BM MNCs. Donor-derived
chimerism in peripheral blood was analyzed
6 weeks after the transplantation. Representative
flow data of the CD45.1/CD45.2 positivity (A) and
the percentages of both donor-derived cells in
myeloid (CD11bpos and/or Gr-1pos) (B, left) and
donor-derived myeloid cells in MNCs (B, right) of
recipient mice are shown.
(C–E) Donor contribution in hematopoiesis of
recipient mice 9 weeks after the transplantation.
Representative flow data of the CD45.1/CD45.2
positivity with the percentages of donor-derived
CD45.1negCD45.2pos cells (C, left) are shown.
Mean percentages ± SD of donor-derived cells in
MNCs (C, right), myeloid cells (D), B cells (E, left),
and T cells (E, right) are shown (n = 10 for littermate
controls and n = 15 for miR-22F/+;Mx1-Cre).
(F) c-Kitpos cells are observed in peripheral blood
of recipient mice transplanted with KSL cells from
miR-22F/+;Mx1-Cre mice. Representative flow cy-
tometry data of c-Kit positivity in donor-derived
cells (left) and the percentages of c-Kitpos cells in
donor-derived cells (right) are shown. (n = 10 for
littermate controls and n = 15 for miR-22F/+;
Mx1-Cre).
All error bars represent ± SD. See also Figures
S2E, S2F, and S7.
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Regulation of TET2 by miR-22 in Hematopoiesis6 weeks posttransplantation, an increased chimerism was
observed in all BM MNCs as well as within the myeloid fraction,
and by 9 weeks this effect was also evident in the c-Kitpos
fraction (Figures 2A–2F). Taken together, these data strongly
suggest that miR-22 enhances the self-renewal capacity of
HSPCs in vivo.
miR-22 Triggers MDS-like Syndromes and
Hematological Malignancies In Vivo
To further test whether increased aberrant hematopoiesis
caused by miR-22 overexpression ultimately progresses to
malignant hematological disease, we continued to follow up
primarily transplanted recipients. Notably, at 12 weeks post-
transplantation, recipient mice transplanted with KSL cells
from miR-22F/+;Mx1-Cre donors, but not from Mx1-Cre donors,
developed an illness that closely resembled human MDS, as
characterized by defective erythroid maturation and anemia,
splenomegaly with myeloid infiltration, low white blood cell
(WBC) counts, and dysplastic myeloid cells in the peripheral90 Cell Stem Cell 13, 87–101, July 3, 2013 ª2013 Elsevier Inc.circulation (Figure 3 and Figures S2G
and S2H). To determine whether this dis-
order is transplantable, the donor-derived
KSL cells resorted from primary recipient
mice were subjected to a secondary
transplantation using fresh competitor
cells. In agreement with our earlier re-
sults, all secondary recipients developeda lethal hematological disease within 4 weeks after secondary
transplantation (Figure S2I).
Furthermore, we also monitored disease onset and pro-
gression to malignancy in miR-22 transgenic mice. The devel-
opment of disease similar to that found in our chimeric
transplantation model was observed in miR-22F/+;Mx1-Cre
mice but not Mx1-Cre littermate controls at 8 months after
pIpC administration: the hallmarks of this distress included
dysplasia in many lineages including erythroid, myeloid, and
platelet; splenomegaly; and an increased number of c-Kitpos
undifferentiated blastic cells in the peripheral blood (Fig-
ures 4A–4C). By 16 months after pIpC administration, all
miR-22 transgenic mice had developed MDS, affecting
multilineage hematopoiesis. Importantly, 13% of mice
succumbed to myeloid leukemia as well as T cell lymphoma
by 11 months, and all miR-22 transgenic mice suffered from
hematological abnormality by 16 months. Finally, 70% of
miR-22 transgenic mice developed myeloid leukemia within
2 years (Figures 4D–4G).
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Figure 3. miR-22 Overexpression Develops
Hematological Syndromes
(A and B) miR-22 overexpression leads to human
MDS-like phenotypes characterized by defective
erythropoiesis (A) and cytopenia (B) in miR-22
transgenic mice. After pIpC administration, 1,500
KSL cells from miR-22F/+;Mx1-Cre mice or litter-
mate controls were transplanted into lethally irra-
diated Ly45.1 recipient mice with 4 3 105 Ly45.1/
Ly45.2 competitor BM MNCs (n = 10 for littermate
controls and n = 15 for miR-22F/+;Mx1-Cre).
Twelve weeks after transplantation, peripheral
blood of recipient mice was evaluated. Repre-
sentative flow data of the Ter119/CD71 positivity
(A, left) and the percentages of R1 (Ter119neg
CD71pos) (A, middle) and R2 (Ter119posCD71pos)
(A, right) are shown.White blood cell (WBC) (B, left)
and platelet (Plt) counts (B, right) are also shown.
(C and D) SplenomegaIy and myeloid infiltration
into spleen were observed in recipient mice
transplanted with KSL cells from miR-22F/+;Mx1-
Cre mice. Representative images of spleens (C,
left), spleen weight (n = 3) (C, right), and repre-
sentative flow data of the positivity of c-Kit and
CD11b and/or Gr-1 in spleen (D) are shown.
(E) miR-22 expression leads to a differentiation
defect in erythroid compartment. Representative
flow data of the Ter119/CD71 positivity in spleen
are shown.
All error bars indicate ± SD. See also
Figures S2G–S2I.
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Regulation of TET2 by miR-22 in HematopoiesisWe also confirmed that the disease was triggered by miR-22
from KSL cells sorted from miR-22-expressing colonies. To
this end, miR-22-expressing cells were subjected to consecu-
tive colony replating and at the sixth replating, the residual
c-KitposLinneg (KL) cells were transplanted into lethally irradiated
recipient mice (Figure S3A). Consistent with our in vivo miR-22
transgenic mice data, by 14 weeks after transplantation, recip-
ient mice transplanted with miR-22-expressing cells developed
myeloid leukemia, as characterized by increased myeloid
blasts in the peripheral blood, defective erythroid maturation
and anemia, splenomegaly with the infiltration of myeloid
blasts, and increased c-Kitpos blasts in bone marrow (Figures
S3B–S3H). Taken together, these data strongly suggest that
miR-22 can enhance HSPC function and contribute to leukemia
development in vivo.
miR-22 Directly Targets TET2 and Affects the
Epigenetic Landscape of the Hematopoietic
Compartment In Vivo
To identify relevant molecular targets of miR-22, we next
undertook a bioinformatic analysis using TargetScan 6.0
(http://targetscan.org) (Lewis et al., 2005), microRNA.org
(http://www.microrna.org/microrna) (Betel et al., 2008), and
miRBase (http://www.mirbase.org) (Griffiths-Jones et al.,
2006). Among various potential targets, we focused on ten
eleven translocation 2 (TET2) as it possesses critically conserved
nucleotides indicative of a legitimate target (Figure S4A). We
then confirmed a direct interaction of miR-22 with the 30UTRregion of the TET2 gene by luciferase reporter assay (Figure S4B
and Song et al., 2013). TET2 is a member of the TET methylcyto-
sine dioxygenase family, which catalyzes the conversion of
5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC).
TET proteins have been implicated in epigenetic reprogramming,
embryonic stem cell maintenance, and early development
(Ficz et al., 2011; Ito et al., 2010). Importantly, recurrent TET2
mutations have been identified in a variety of hematological
malignancies including MDS, MPN, CMMoL, and AML (Abdel-
Wahab et al., 2009; Delhommeau et al., 2009; Jankowska
et al., 2009; Tefferi et al., 2009). It is noteworthy that the pheno-
types elicited by miR-22 overexpression closely phenocopy
the inactivation of Tet2 in the hematopoietic system both
in vitro and in vivo (Li et al., 2011; Moran-Crusio et al., 2011;
Quivoron et al., 2011). It has also been documented that Tet2
expression is increased during hematopoietic differentiation,
and conversely, that miR-22 is highly expressed in HSPCs
while its expression declines in mature cells (Figure S4C,
Moran-Crusio et al., 2011). We therefore tested whether
miR-22 could act as an authentic TET2-targeting miRNA in the
hematopoietic compartment by utilizing our conditional trans-
genic mouse model. To this end, we measured Tet2 expression
in the peripheral blood and bone marrow of miR-22F/+;Mx1-Cre
or Mx1-Cre littermate mice at 2–3 weeks after pIpC administra-
tion. Importantly, real-time qPCR and western blot analyses
revealed a marked reduction in levels of Tet2 mRNA and protein,
respectively, inmiR-22F/+;Mx1-Cremice compared to littermate
controls (Figures 5A, 5B, 5E–5G and Figure S4D).Cell Stem Cell 13, 87–101, July 3, 2013 ª2013 Elsevier Inc. 91
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Figure 4. miR-22 Transgenic Mice Develop Primary Hematological Diseases
(A and B) miR-22 transgenic mice develop MDS-like hematological syndromes. Representative smears of peripheral blood of 8-month-old mice after pIpC
administration are shown (A). Representative images of dysplastic erythroid cells (poikilocytosis, A; polychromasia, B-i, arrowhead), dysplastic platelets (giant
platelet, B-i, arrow, B-vii), dysplastic neutrophils (hypersegmented neutrophils, B-ii-iv, arrows; a pseudo-Pelger-Huet anomaly, B-v and vi) and dysplastic blasts
(B-viii arrows) in miR-22 transgenic mice are also shown. Scale bars, 50 mm (A) and 10 mm (B).
(C) c-Kitpos immature blasts are increased in miR-22 transgenic mice. Representative flow cytometry data (left) and mean percentages ± SD of c-Kitpos cells in
Linneg compartment (right) are shown (n = 3).
(D) Disease-free survival of miR-22F/+;Mx1-Cre mice (n = 26) and littermate controls (n = 13).
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Regulation of TET2 by miR-22 in HematopoiesisOn the basis of these observations, we then sought to deter-
mine whether miR-22-mediated TET2 inactivation is sufficient
to impact the global epigenetic landscape in blood cells. We
therefore analyzed 5-hmC and 5-mC levels in the genomic
DNA of miR-22F/+;Mx1-Cre mice. Immunofluorescence and dot
blot analyses revealed a drastic (more than 2-fold) reduction in
5-hmC levels and a concomitant increase in 5-mC levels in
bone marrow of these mice (Figures 5C and 5D), suggesting
that changes in an important epigenetic mark (e.g., 5-hmC)
may contribute to the ability of miR-22 to affect hematopoiesis
and leukemogenesis.
To further understand the consequences of repression of
TET2 by miR-22 in hematopoiesis, we next examined the effects
of miR-22 overexpression on putative targets of TET2 (Kallin
et al., 2012; Ko et al., 2010; Yamazaki et al., 2012). A comprehen-
sive real-time qPCR analysis revealed that the expression levels
of a substantial number of putative Tet2 target genes, including
Aim2, Hal, Igbt2, and Sp140, were markedly decreased in the
HSC compartment (CD150posCD48negFlt3negCD34negKSL cells)
purified from miR-22F/+;Mx1-Cre mice (Figure 5E and Fig-
ure S4E). Interestingly, absence in myeloma 2 (AIM2) has been
reported to have a role in the reduction of cell proliferation
by cell cycle arrest and to also be highly methylated in MDS,
especially in CMMoL patients with TET2 mutations (Figueroa
et al., 2010; Patsos et al., 2010; Yamazaki et al., 2012). Therefore
we hypothesized that its silencing via methylation of the pro-
moter might provide a growth advantage to cancer cells. Addi-
tionally, polymorphisms of SP140 (SP140 nuclear body protein)
have been found to correlate with chronic lymphoid leukemia,
and its hypermethylation has been also demonstrated in
CMMoL patients with TET2 mutations, and hence its hyperme-
thylation may influence the risk of leukemogenesis (Di Bernardo
et al., 2008; Ko et al., 2010; Yamazaki et al., 2012). Indeed, we
confirmed that the expression of Aim2 and Sp140was drastically
reduced at the levels of mRNA and protein in the bone marrow
of miR-22F/+;Mx1-Cre mice compared to littermate controls,
and this reduction was associated with an increase in promoter
methylation (Figures 5F and 5G and Figure S4F). Taken together,
these results suggest that miR-22 represses TET2 expression
and thereby can remodel the epigenetic landscape with global
changes in 5-hmC levels and alteration in the expression of
putative TET2 target genes including AIM2 and SP140.
miR-22 Enhances Stem Cell Function and Triggers
Hematological Transformation through Repression
of TET2
Next, we explored the relevance of the crosstalk between
miR-22 and TET2 in hematopoiesis and hematological malig-
nancies. To test whether TET2 directly contributes to the func-
tion of miR-22 in the hematopoietic compartment, we first
infected KSL cells isolated from wild-type mice with a retroviral
vector encoding miR-22 and GFP. After the resorting, GFP+KSL
cells were additionally infected with a TET2-expressing lentiviral(E and F) Representative lethal hematological syndromes observed in miR-22 t
(E, right) are shown. Scale bars, 100 mm. Representative smears of peripheral bloo
also shown. Scale bars, 20 mm.
(G) Pie charts representing the disease spectrum in miR-22F/+;Mx1-Cre mice at
All error bars indicate ± SD. See also Figure S3.particle. In vitro colony replating and LTC-IC assays demon-
strated that the phenotypes caused by miR-22 overexpression
in hematopoietic compartment are potently suppressed by
ectopic expression of TET2 (Figures S4G–S4J). Notably, an
in vivo transplantation assay revealed that ectopic expression
of TET2 leads to survival advantages for recipient mice trans-
planted with miR-22-expressing KSL cells (Figure S4K).
To further examine this interaction, we purified KSL cells from
miR-22 transgenic mice and infected them with a retroviral
vector encoding Cre recombinase and GFP. After the resorting
of GFP+KSL cells, cells were additionally infected with a TET2-
expressing lentiviral particle and the resulting phenotypes
were analyzed. In vitro colony replating and LTC-IC analyses
demonstrated that the oncogenic function of miR-22 was
antagonized by ectopic expression of TET2 (Figures 6A and
6B). Notably, when KSL cells of miR-22F/+ mice were simulta-
neously coinfected with a Cre recombinase construct and a
TET2-expressing construct, ectopic expression of TET2 more
strikingly impaired the replating potential of GFP+KSL cells (Fig-
ures S5A and S5B). In line with these observations, an in vivo
transplantation assay revealed significant survival advantages
in recipient mice transplanted with miR-22F/+ KSL cells coin-
fected with Cre and TET2 compared to those with miR-22F/+
KSL cells coinfected with Cre and control vector (Figure 6C).
Importantly, the positive survival effect drawn by ectopic
expression of TET2 was more pronounced in secondary trans-
plantation (Figure S5C).
Finally, we purified KSL cells from miR-22 transgenic mice
after pIpC administration, infected them with a TET2-express-
ing lentiviral particle, and evaluated the resulting phenotypes
(Figure 6D). We found that all the phenotypes elicited by an
elevation of miR-22 in vitro and in vivo in hematopoietic
compartment, including repression of the expression of
Aim2 and Sp140 in bone marrow, were also significantly sup-
pressed by ectopic expression of TET2 (Figures 6E–6H and
Figure S5D).
Importantly, when we purified KSL cells from primary miR-22
transgenic mice and infected them with TET2 followed by in vivo
transplantation together with competitor cells, ectopic expres-
sion of TET2 delayed the onset of hematological disorder and
was accompanied by significant advantages in disease-free
survival (Figure S5E). Taken together, these data suggest that
TET2 is one of the major targets responsible for the miR-22
proto-oncogenic function in hematopoiesis and the develop-
ment of hematological malignancies.
miR-22 Decoying Offers Therapeutic Opportunities
and Its Overexpression Correlates with the Silencing
of TET2 Protein in MDS and AML Patients
Next, we investigated whether the miR-22/TET2 interaction may
offer a therapeutic opportunity for the treatment of hematological
malignancies. We therefore tested whether inhibition of miR-22
affects TET2 expression and activity, as well as the biology ofransgenic mice. Representative images of spleens (E, left) and H&E staining
d ofmiR-22 transgenicmice (6months old) with increasedmyeloid blasts (F) are
the indicated ages (n = 26). MPN, myeloproliferative neoplasm.
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Figure 5. miR-22 Acts as an Epigenetic Modifier by Directly Targeting TET2
(A and B) A reduction in the levels of Tet2 mRNA in miR-22 transgenic mice. Expression levels of miR-22 (left) and Tet2 mRNA (right) in mononuclear cells from
peripheral blood (A) and bone marrow (BM) (B) ofMx1-Cre control ormiR-22F/+;Mx1-Cremice 2–3 weeks after pIpC administration were determined by real-time
qPCR (n = 6).
(C) miR-22 expression results in a significant reduction in the levels of 5-hmC in the hematopoietic compartment. 5-hmC and 5-mC were evaluated by
immunofluorescence analysis in BM cells isolated frommiR-22F/+;Mx1-Cremice and littermate controls 3 weeks after pIpC administration (left). Cells expressing
high levels of 5-hmC show low levels of 5-mC (arrow) and conversely, cells expressing low levels of 5-hmC exhibit high levels of 5-mC (arrowhead). Bar graph
depicts mean percentages ± SD of cells expressing high levels of 5-hmC (n = 3) (right). Scale bars, 10 mm.
(legend continued on next page)
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Regulation of TET2 by miR-22 in Hematopoiesisleukemias. To this end, we inhibited miR-22 in human leukemia
cell lines, K562 and U937, both of which express relatively high
levels of miR-22 (Figure S5F, Wang et al., 2012), by using a
miR-22 retroviral sponge or a custom-made locked nucleic
acid (LNA; Petersen and Wengel, 2003) miR-22 decoy as the
miR-22 sponge. Critically, inhibition of miR-22 in human
leukemic cells resulted in a significant reduction in cell prolifera-
tion and an elevation of the expression of TET2 and its targets,
AIM2 and SP140 (Figures 6I and 6J and Figures S5G–S5I). It is
worth noting that the U937 cell line harbors phosphatase and
tensin homolog (PTEN) mutant with premature termination of
coding sequence (Liu et al., 2000). Hence in this setting the ef-
fects observed upon miR-22 decoying are not mediated by the
ability of miR-22 to downregulate PTEN expression.
In full agreement with these observations, an in vitro colony re-
plating assay revealed that the inhibition of miR-22 by a miR-22
retroviral sponge in KSL cells purified from miR-22 transgenic
mice led to a reduction in their colony-forming capability (Fig-
ure S5J). Taken together, these data provide a rationale for the
therapeutic potential of targeting miR-22 with LNAmiR-22 inhib-
itors in the treatment of hematological malignancies.
The pathological roles of TET2 in myeloid malignancies have
been previously highlighted as its mutations are widely observed
in myeloid malignancies and MDS patients. Most of these earlier
studies, however, were limited tomutation analysis and found lit-
tle relationship between the progression of MDS to AML and
TET2 expression levels, although the phenotypes of Tet2
knockout mice gave indications to the contrary (Moran-Crusio
et al., 2011; Quivoron et al., 2011). Likewise, emerging evidence
demonstrated no significant prognostic association between
TET2 mutations in MDS patients and WHO subtypes, the Inter-
national Prognostic Scoring System (IPSS) score, cytogenetic
status, or transformation to AML (Kosmider et al., 2009; Smith
et al., 2010).
However, on the basis of our data we hypothesized that amiR-
22-dependent reduction in the levels of TET2 might have been
overlooked and could play a key role in the development of
myeloid malignancies. To test this hypothesis, we investigated
a large cohort of patients with MDS by an immunohistochemical
analysis. Strikingly, this analysis revealed that60%of 107MDS
patients analyzed displayed a reduction in the levels of TET2
(36% of 107 MDS patients show Score 1 and 24% show Score
2) and that this reduction was directly correlated with poor sur-
vival rates of patients (Figures 7A and 7B and Figures S6A–
S6D). Importantly, the percentage of blasts distributed in each
WHO category of MDS stage was not directly associated with
expression level of TET2, but a significant correlation was found
between TET2 expression and poor survival rates within each
WHO classification, as well as among MDS patients harboring
a normal karyotype, suggesting that the poorer survival expec-(D) miR-22 expression leads to a significant reduction in global 5-hmC expression
dot blot assay with genomic DNA purified from BM cells of miR-22F/+;Mx1-Cre o
(E) Plots depict relative expression levels of putative Tet2 target genes (Aim
miR-22F/+;Mx1-Cre mice and littermate controls 2–3 weeks after pIpC administ
an internal control, respectively.
(F and G) Repression of putative downstream genes of Tet2 in miR-22 transgenic
BM of miR-22F/+;Mx1-Cre mice or littermate controls 2–3 weeks after pIpC adm
All error bars indicate ± SD. See also Figures S4A–S4F.tancy linked to TET2 downregulation does not simply reflect con-
founding factors, such as blast count and cytogenetic karyotype
(Figure 7C and Figures S6E and S6F). Together, these results
suggest that the contribution of TET2 to the pathogenesis of
hematological malignancies extends far beyond the initial impact
of its mutations.
Importantly, combined in situ hybridization and immunohisto-
chemical analyses revealed that miR-22 expression was directly
anticorrelated with the levels of TET2 in a large-cohort data set
of MDS patients (n = 107) (Pearson’s r = 0.47, p = 2.4 3
107): 28% of MDS patients that showed the reduced levels of
TET2 (Score 1) also exhibited high miR-22 levels (Score 3)
(Figure 7D and Figure S6G and see also Figure 1A).
Furthermore, because our in vivo analysis demonstrated that
miR-22 triggers overt leukemia (Figure 4G), we investigated
the miR-22/TET2 interactive relationship in AML with multiple
lineage dysplasia (MLD) (n = 18). Our combined analyses of
in situ hybridization and immunohistochemistry revealed a
clear anticorrelation between miR-22 expression and the levels
of TET2 (Pearson’s r = 0.75, p = 2.9 3 104); in addition,
22.2% of AML with MLD patients showing the reduced levels
of TET2 (Score 1) displayed a high expression of miR-22 (Score
3) (Figure 7E). Western blot and real-time qPCR analyses also
corroborated a relationship betweenmiR-22 and TET2 in primary
AML patients (Figure S6H). Finally, we confirmed these findings
by analyzing the expression levels of miR-22 in a very large
cohort of AML patients from a previously reported real-time
qPCR database (Jongen-Lavrencic et al., 2008). Here miR-22
was found highly expressed in 58.1% of 214 AML patient
samples compared to normal bone marrow from healthy donors
(p = 0.028, Figure 7F). Taken together, these data strongly sug-
gest that aberration of the miR-22-TET2 regulatory network is
one of the common events in hematopoietic malignancies.
DISCUSSION
The findings presented in this study point to a number of impor-
tant conclusions.
The first of these is thatmiR-22 is a powerful regulator of HSPC
maintenance and self-renewal. These effects are so pronounced
that miR-22-expressing HSPCs out-competed their wild-type
counterparts in all the assays that we performed in vivo as well
as in vitro. Importantly, in so doing miR-22 also skews hemato-
poietic differentiation, mainly toward myeloid compartment.
We have also identified miR-22 as a key determinant of the
pathogenesis of both MDS and hematological malignancies.
Remarkably, miR-22 plays a role in the initiation of MDS as
well as full-blown leukemia; hence it exerts a bona fide proto-
oncogenic activity. MDS is a genetically heterogeneous disease
and we are only now beginning to fully appreciate its diversity.levels in the genome in BM cells. 5-hmC levels were analyzed by quantitative
r littermate control mice.
2, Sp140, Igbt2, and Hal) in CD150posCD48negFlt-3negCD34negKSL cells of
ration (n = 4). Ly6c1 and Actb were used as a Tet2 unrelated gene control and
mice. Expression levels of Tet2, Sp140, and Aim2 mRNAs (F) or proteins (G) in
inistration were evaluated (n = 3).
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Regulation of TET2 by miR-22 in HematopoiesisThis study will therefore help in the reclassification of subtypes of
MDS, and possibly AML, on the basis of miR-22 expression.
Furthermore, our comprehensive analysis ofMDS patients has
identified TET2 protein downregulation as a common event in
hemopoietic malignancy (35.5% of total MDS patient samples,
and 22.2% of AML samples with MLD, with most of those pa-
tients exhibiting high expression of miR-22) and a factor in
poor prognosis, findings which directly impact the management
and therapeutic decisions for patients with myeloid malig-
nancies. Our findings thus imply that the contribution of TET2
to the pathogenesis of myeloid malignancies could be related
to more than its mutations and identify the deregulation of the
miR-22-TET2 pathway as one of the most frequent events in he-
matological malignancies. Importantly, they also provide a
compelling rationale for targeted therapies that impact the
mechanisms of regulation responsible for the control of TET2
levels (e.g., through miR-22 decoying).
We show that miR-22 negatively regulates the expression of
TET2 and that its overexpression closely phenocopies, both
in vitro and in vivo, many of the characteristics observed upon
inactivation of TET2 (Figure 7G). Extensive mouse modeling ef-
forts support these similarities both in our current study and in
other Tet2-related studies (Li et al., 2011; Moran-Crusio et al.,
2011; Quivoron et al., 2011). Furthermore, our comprehensive
analyses of a large cohort of MDS and AML patients likewise
have demonstrated this antagonistic crosstalk.
miR-22 also appears to exert a tumor-promoting role in other
tissues, including mammary glands, through its ability to sup-
press the expression of other TET family members such as
TET1 and TET3 (Figure S4D and Song et al., 2013). Thus, miR-
22 contributes to inactivation of TET2 and other TET family mem-
bers in tumorigenesis, representing a tumorigeneic pathway in
addition to the more familiar ones of TET2 and TET family muta-
tions and deletions.
We previously demonstrated that miR-22 also targets the
PTEN tumor suppressor (Poliseno et al., 2010). Pten loss has
also been implicated in the pathogenesis of hematological
malignancies (Yilmaz et al., 2006; Zhang et al., 2006). However,
miR-22 through TET2 regulation can bestow to hemopoietic cells(C) TET2 attenuates the hematopoietic malignancies induced by miR-22 overex
or GFP control vector before TET2 infection, and 1,500 GFP+KSL cells were tra
mononuclear cells (BM MNCs). Disease-free survival of recipient mice was exa
p values.
(D) Overview of the experimental design for introduction of TET2 into KSL cells from
subjected to infection with TET2-expressing vector, and their characteristics we
(E) Colony-forming capacity of miR-22 transgenic progenitor cells is attenuated by
cells from miR-22F/+;Mx1-Cre mice were infected with TET2-expressing vector a
The resulting colony numbers were scored in three independent littermate pairs
(F and G) Ectopic expression of TET2 causes a reduction in LTC-IC capacity of mi
Cremice or littermate controls, as shown in Figure 6D, were cocultured with strom
after coculture (n = 3) (F). At the indicated times after coculture, the capacity of c
(H) Increased reconstitution capacity of KSL cells of miR-22 transgenic mice is red
Cre mice or littermate controls were infected with TET2-expressing vector. 1 3
with 5 3 105 competitor BM MNCs. Representative flow cytometry data of the C
(I) Inhibition of miR-22 increases the expression of TET2 and its putative target ge
miR-22 sponge or control sponge, and 48 hr after the infection, cell lysates were
(J) Inhibition of miR-22 suppresses the proliferation of human leukemic cells. K
sponge. Forty-eight hours after puromycin selection, 5 3 104 cells were incub
indicated times (n = 3).
All error bars indicate ± SD. See also Figures S4G–S4K and S5.further competitive advantage as also supported by the fact that
miR-22 decoying suppresses proliferation even in a PTEN
mutant setting (Figure S5I). This may in turn explain the potent
proto-oncogenic activity of miR-22. Indeed, there are several
intriguing phenotypical differences between PtenF/F;Mx1-Cre
and miR-22F/+;Mx1-Cre mouse models that could illuminate a
unique and powerful role exerted by miR-22 in leukemogenesis.
First, miR-22 increased the ability of HSCs to repopulate, which
was then followed by leukemia development, whereas loss of
Pten resulted in the exhaustion of normal HSCs. In addition,
while Pten loss induces short-term expansion in HSCs through
excessive cell cycle entry followed by exhaustion, no significant
alteration in the stem cell compartment was observed at 2–
3weeks after the introduction ofmiR-22 (Figure S7). Additionally,
while loss of Pten in HSCs is known to lead to MPN-like disease
followed by leukemia development, hematological dysplasia
with ineffective hematopoiesis is one of the main phenotypes
caused bymiR-22 expression, with bicytopenia or pancytopenia
observed in miR-22 transgenic mice. Furthermore, although
HSCs from PtenF/+;Mx1-Cre mice are known to be transplant-
able, the recipients do not develop hematopoietic syndromes
(Yilmaz et al., 2006). In contrast, recipient mice transplanted
with HSCs purified from miR-22F/+;Mx1-Cre mice developed
aberrant hematopoiesis followed by MDS and leukemia. Hence,
the ability of miR-22 to concomitantly downregulate TET2 and
PTEN provides it a unique mode of action and confers on it
the ability to overcome PTEN-loss-driven stem cell exhaustion
while favoring MDS development and leukemogenesis. This in
turn raises the possibility that concomitant silencing of TET2
and PTEN by miR-22 could represent a powerful event underly-
ing the pathogenesis of human cancer, as it may overcome
the fail-safe mechanisms elicited by loss of PTEN (Berger
et al., 2011).
Finally, since the technology to inhibit miRNAs for therapy is
rapidly evolving (Elme´n et al., 2008; Stenvang et al., 2008), this
will impact treatment options for a range of diseases and disor-
ders in the years to come. Indeed, LNA-based miRNA decoying
has already come of age for the treatment of hepatitis C (Lanford
et al., 2010) and may prove very effective for the treatment ofpression. KSL cells sorted from miR-22F/+ mice were infected with Cre-GFP
nsplanted into recipient mice with 2.0 3 105 Ly45.1 competitor bone marrow
mined by Kaplan-Meier survival curves. Log-rank test was used to generate
miR-22 transgenicmice. KSL cells purified frommiR-22 transgenic mice were
re evaluated in vivo and in vitro.
ectopic expression of TET2. Two weeks after pIpC administration, sorted KSL
nd resorted KSL cells were then subjected to incubation in semisolid medium.
in the indicated platings (n = 3). N.D., nondetectable.
R-22 transgenic progenitor cells. TET2-infected KSL cells frommiR-22F/+;Mx1-
al cells for the indicated weeks. Maintained KSL cells were evaluated 2 weeks
olony formation was also determined in semisolid medium (n = 3) (G).
uced by ectopic expression of TET2. The sorted KSL cells frommiR-22F/+;Mx1-
104 KSL cells were resorted and subjected to bone marrow transplantation
D45.1/CD45.2 positivity at 6 weeks after transplantation are shown.
nes in human leukemic cells. K562 cells were infected with the vector encoding
subjected to immunoblot analysis for the indicated proteins.
562 cells were infected with the vector encoding miR-22 sponge or control
ated for seven days. Optical densities of the cells were determined at the
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Figure 7. miR-22 Overexpression Directly Correlates with the Silencing of TET2 in Human MDS and AML Patients
(A) TET2 expression is downregulated in human MDS patients. Expression levels of TET2 protein in CD34pos blasts in subtypes of MDS were evaluated by
immunohistochemical analysis. Representative images of immunohistochemical analysis for TET2 protein in patients with subtypes of MDS are shown (left).
Insets represent TET2 staining in blasts (arrow with B) with a high magnification. Scoring the expression levels of TET2 in blasts was performed as described
in Supplemental Experimental Procedures (right). The data were analyzed by Chi-square test. r, Pearson’s r. Scale bars, 60 mm.
(B) Downregulation of TET2 levels correlates with poor survival rates of human MDS patients. Overall survival of patients that express low TET2 (TET2 Score 1,
n = 38, red) or high TET2 (TET2 Score 2 or 3, n = 69, blue) is shown. p value was generated by a log-rank test.
(C) Survival rates of low TET2 (Score 1) and high TET2 (Score 2 or 3) patients with RA (left), RAEB-1 (middle), and RAEB-2 (right). Survival rate of the p value
was generated by a log-rank test.
(legend continued on next page)
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Regulation of TET2 by miR-22 in Hematopoiesisblood-borne diseases (Zhang et al., 2012). The data presented in
this study thus support the notion that an LNA-based therapeutic
targeting of miR-22 may represent an effective strategy for TET2
reactivation as a treatment modality for incurable diseases such
as MDS and leukemia.
EXPERIMENTAL PROCEDURES
Mice
The details of generation of miR-22 transgenic mice are described in the
Supplemental Experimental Procedures. C57BL/6 mice (B6-CD45.2) and
C57BL/6 mice congenic for the CD45 locus (B6-CD45.1) were purchased
from The Jackson Laboratory and used as recipients in the transplantation
assay.
Real-Time qPCR
The details of RNA isolation and real-time qPCR analysis are described in the
Supplemental Experimental Procedures.
Immunofluorescence
Cells were fixed and stained as described (Ko et al., 2010). The details of
staining of cells and the sources of antibodies used are also described in the
Supplemental Experimental Procedures.
Flow Cytometry
The sources of antibodies used for flow cytometric analysis are described in
the Supplemental Experimental Procedures.
Long-Term Cultures and In Vitro Colony-Forming Assays
The details of colony replating assays are described in the Supplemental
Experimental Procedures.
Competitive Reconstitution Assay
The details of competitive reconstitution assay are described in the Supple-
mental Experimental Procedures.
Human Sample Analysis
Human patient samples were analyzed as described in detail in the Supple-
mental Experimental Procedures. This study was approved by the Institutional
Review Board waiver and Human Tissue Utilization Committee, and clinical
and hematological data were recorded after patients provided their informed
consent in accordance with the Declaration of Helsinki.
miRNA In Situ Hybridization
The details of in situ hybridization analysis for miR-22 are described in the
Supplemental Experimental Procedures.
Immunohistochemistry
The details of immunohistochemical analysis are described in the Supple-
mental Experimental Procedures.
Dynamic Transcriptome Analysis
The details of dynamic transcriptome analysis are described in the Supple-
mental Experimental Procedures.(D) miR-22 overexpression correlates with downregulation of TET2 in MDS patien
hybridization and immunohistochemical analyses, and the expression levels of m
Pearson’s r.
(E) The expression levels of miR-22 and TET2 in 18 AML with MLD patient sampl
AML, acute myeloid leukemia; MLD, multiple lineage dysplasia.
(F) miR-22 is highly expressed in human AML patients. Expression levels of miR-2
(n = 215) are shown.
(G) Proposed model of oncogenic role of miR-22 in hematopoiesis. miR-22 nega
potentiation of global gene methylation. This genetic remodeling in turn enhance
poietic stem cells; LIC, leukemia-initiating cells.
See also Figure S6.Methylation-Specific PCR
DNA methylation status of Sp140 in purified KSL cells (or Linneg cells) was
examined by the methylation-specific PCR with genomic DNA treated with
sodium bisulfite using the EZ DNA Methylation-Direct kit (Zymo Research).
Primer sequences were previously described (Yamazaki et al., 2012). b-actin
was used as an internal control of genomic DNA.
Luciferase Reporter Assay
The details of the luciferase reporter assay are described in the Supplemental
Experimental Procedures.
Statistical Analysis
Student’s t test was utilized to determine statistical significance unless other-
wise specified. p < 0.05 was considered statistically significant.SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes Supplemental Experimental
Procedures and seven figures and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2013.06.003.
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